More News
Vice President Kamala Harris on Saturday put the focus on the dangers of a second…
Discover
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Britain’s newly appointed cabinet ministers have begun to arrive in Downing Street for the first meeting of Sir Keir Starmer’s top team after his decisive election victory over the Conservatives.Having vowed to…
Spotlight
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Labour has won a historic landslide victory in the UK general election, returning to government after 14 years in opposition.Party leader Sir Keir Starmer, who will become prime minister later on Friday,…
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing chronic hepatitis B [cHBV] therapies. ABUS’ strategy is three-pronged: suppressing HBV DNA replication, reducing viral antigens like HBsAg with RNA interference drugs, and boosting the immune response using immune modulators. The company’s leading drug is Imdusiran [AB-729], and…
More Topics
Business ➤
Economists don’t believe job gains will fall off a cliff when the Bureau of Labor…
Investing ➤
Key News Asian equities had a strong day as Japan outperformed, and Hong Kong posted…
Markets ➤
Snowflake — a mobilizer of enterprise data through a company’s data cloud — exceeded investor…
Economy ➤
WASHINGTON (Reuters) – Sales of new U.S. single-family homes fell more than expected in October,…
Latest Videos
